Developer docs
API playgroundTry for free, no card

Search company profiles

Werewolf Therapeutics

Full company profile

uuid0000823

Namestring
Werewolf Therapeutics
Legal namestring
Werewolf Therapeutics, Inc.
Websiteurl
werewolftx.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Werewolf Therapeutics is a clinical-stage oncology biopharmaceutical company founded in 2017 and headquartered in Watertown, Massachusetts. It trades on NASDAQ under the ticker HOWL. The company develops conditionally activated proinflammatory immune modulators — INDUKINE™ molecules — and conditionally activated T cell engagers — INDUCER™ molecules — designed to remain inactive in peripheral tissue and activate selectively in the tumor microenvironment. These candidates are built on the company's proprietary PREDATOR® protein engineering platform, which integrates masking, tumor-selective protease activation, and half-life extension elements into single systemically delivered molecules intended to limit the off-target toxicities that have historically constrained cytokine-based therapies such as IL-2, IL-12, IL-18, and IL-21.

The clinical pipeline is led by WTX-124, a conditionally activated IL-2 INDUKINE in Phase 1/1b for advanced solid tumors including heavily pretreated melanoma (where it has shown a 21–30% objective response rate and received FDA Fast Track Designation), and WTX-330, a conditionally activated IL-12 INDUKINE in Phase 1b/2 for advanced solid tumors and lymphoma. Earlier-stage assets include WTX-712 (IL-21), WTX-518 (IL-18), WTX-921 (IL-10, for inflammatory bowel disease), and INDUCER programs WTX-1011 (STEAP1, prostate cancer) and WTX-2022 (CDH6, ovarian and kidney cancers). JZP898 (formerly WTX-613, an IFNα INDUKINE) has been out-licensed to Jazz Pharmaceuticals and is in Phase 1 development.

The company has reported $0 in collaboration revenue for FY2025 against a $60.8M net loss, with $57.1M in cash as of December 31, 2025 providing runway into Q4 2026. There are no commercial products; the only revenue mechanism historically is out-licensing. In February 2026 the board approved a 64% workforce reduction, the CFO and CMO resigned, Piper Sandler was engaged to explore strategic alternatives (sale, merger, or licensing), and the company received a Nasdaq deficiency notice for failing the $1.00 minimum bid price requirement, with compliance required by August 3, 2026.

Short descriptiontext

Werewolf Therapeutics is a clinical-stage oncology biopharmaceutical company developing conditionally activated INDUKINE™ cytokine and INDUCER™ T cell engager therapeutics via its proprietary PREDATOR® protein engineering platform, targeting patients with advanced solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology biotherapeutics, cancer immunotherapy, protein engineering platform, clinical-stage pharmaceuticals, tumor microenvironment targeting
Industry2 codes
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-Oncology Biotherapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-Revenue / Clinical Stage
TypeLicensing Royalties
Description

Werewolf Therapeutics is a clinical-stage biopharmaceutical company with no collaboration revenue. The company reported $0M revenue in FY2025 with a net loss of $60.822 million. The company is exploring strategic alternatives including potential sale, merger, licensing deals, or financing to extend operational runway.

tradingview.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Werewolf Therapeutics develops a pipeline of conditionally activated proinflammatory immune modulators (INDUKINE™ molecules such as WTX-124 IL-2 and WTX-330 IL-12) and conditionally activated T cell engagers (INDUCER™ molecules), all engineered using its proprietary PREDATOR® protein-engineering platform. The molecules are designed to remain inactive systemically and activate selectively within the tumor microenvironment, aiming to deliver validated cytokine and T cell-engaging biology while minimizing off-target toxicities for patients with advanced or metastatic solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 21-30% objective response rate in heavily pretreated melanoma patients treated with WTX-124
+2 more records
Product overview1 text field

Werewolf Therapeutics is developing a pipeline of conditionally activated proinflammatory immune modulators called INDUKINE™ molecules and next-generation INDUCER™ T cell engagers for cancer and inflammatory disease treatment. The core PREDATOR® protein engineering technology platform enables systemically delivered therapies that remain inactive in peripheral tissue and activate selectively in the tumor microenvironment. Lead candidates include WTX-124 (IL-2, Phase 1/1b) and WTX-330 (IL-12, Phase 1b/2), with earlier-stage pipeline candidates WTX-712 (IL-21), WTX-518 (IL-18), WTX-921 (IL-10), WTX-1011 (STEAP1 T cell engager), and WTX-2022 (CDH6 T cell engager). A partnered program, JZP898 (IFNα, Phase 1), has been acquired by Jazz Pharmaceuticals.

Product and service1 record
1WTX-124
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Jazz Pharmaceuticals acquired JZP898 (formerly WTX-613), a systemically delivered conditionally activated Interferon alpha (IFNα) INDUKINE molecule being developed for refractory and/or immunologically unresponsive tumors. Werewolf out-licensed this partnered program to Jazz.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial partner conducting Phase 1/1b trial of WTX-124. A patient at HonorHealth achieved complete response and has been in remission for over a year - featured in company's Full Moon Moment campaign.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing conditionally activated antibodies using its SAFEbody® masking platform; comparable in approach to targeting tumor microenvironment while sparing healthy tissue.

TypeDirect peer
Description

Clinical-stage immuno-oncology company leveraging computational platform to develop novel cytokine and immune checkpoint targets; comparable in developing innovative cytokine-based cancer immunotherapies.

TypeDirect peer
Description

Clinical-stage oncology company pioneering Probody® conditionally activated therapeutics with masking technology designed to reduce systemic toxicity—directly comparable to Werewolf's PREDATOR platform and INDUKINE/INDUCER masking approaches.

TypeDirect peer
Description

Clinical-stage company developing Conditionally Active Biologics (CABs) that are activated in tumor microenvironment; comparable conditionally activated protein therapeutic platform targeting solid tumors.

TypeDirect peer
Description

Developed T cell engagers (HPN328, HPN217) for solid tumors using TriTAC platform; comparable T cell engager approach that ultimately validated exit via Merck acquisition, illustrating strategic outcome pathway for Werewolf.

TypeDirect peer
Description

Clinical-stage developer of tumor-activated T cell engagers (TRACTrs); directly comparable INDUCER-style T cell engager mechanism with tumor-selective activation.

TypeDirect peer
Description

Clinical-stage oncology company developing a diversified pipeline of immuno-oncology candidates including cytokine-based therapies; comparable small-cap clinical-stage model exploring strategic partnerships for individual programs.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing novel immunomedicines for solid tumors; comparable small-cap clinical-stage model with similar workforce and pipeline scale.

TypeEmerging player
Description

Pre-clinical/early-clinical developer of conditionally activated T cell engagers (COBRA platform) acquired by Takeda; comparable T cell engager approach with tumor-selective activation in solid tumors, illustrating strategic acquisition path.

10Dragonfly Therapeutics
TypeDirect peer
Description

Developer of cytokine-based immunotherapies including IL-12, IL-15, and IL-21 candidates with TriNKETs platform; directly comparable cytokine-immunotherapy focus overlapping with Werewolf's INDUKINE pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Werewolf Therapeutics

Immuno-Oncology Biotherapeuticswerewolftx.com

Werewolf Therapeutics is a clinical-stage oncology biopharmaceutical company developing conditionally activated INDUKINE™ cytokine and INDUCER™ T cell engager therapeutics via its proprietary PREDATOR® protein engineering platform, targeting patients with advanced solid tumors.

What Werewolf Therapeutics does

Werewolf Therapeutics is a clinical-stage oncology biopharmaceutical company founded in 2017 and headquartered in Watertown, Massachusetts. It trades on NASDAQ under the ticker HOWL. The company develops conditionally activated proinflammatory immune modulators — INDUKINE™ molecules — and conditionally activated T cell engagers — INDUCER™ molecules — designed to remain inactive in peripheral tissue and activate selectively in the tumor microenvironment. These candidates are built on the company's proprietary PREDATOR® protein engineering platform, which integrates masking, tumor-selective protease activation, and half-life extension elements into single systemically delivered molecules intended to limit the off-target toxicities that have historically constrained cytokine-based therapies such as IL-2, IL-12, IL-18, and IL-21.

The clinical pipeline is led by WTX-124, a conditionally activated IL-2 INDUKINE in Phase 1/1b for advanced solid tumors including heavily pretreated melanoma (where it has shown a 21–30% objective response rate and received FDA Fast Track Designation), and WTX-330, a conditionally activated IL-12 INDUKINE in Phase 1b/2 for advanced solid tumors and lymphoma. Earlier-stage assets include WTX-712 (IL-21), WTX-518 (IL-18), WTX-921 (IL-10, for inflammatory bowel disease), and INDUCER programs WTX-1011 (STEAP1, prostate cancer) and WTX-2022 (CDH6, ovarian and kidney cancers). JZP898 (formerly WTX-613, an IFNα INDUKINE) has been out-licensed to Jazz Pharmaceuticals and is in Phase 1 development.

The company has reported $0 in collaboration revenue for FY2025 against a $60.8M net loss, with $57.1M in cash as of December 31, 2025 providing runway into Q4 2026. There are no commercial products; the only revenue mechanism historically is out-licensing. In February 2026 the board approved a 64% workforce reduction, the CFO and CMO resigned, Piper Sandler was engaged to explore strategic alternatives (sale, merger, or licensing), and the company received a Nasdaq deficiency notice for failing the $1.00 minimum bid price requirement, with compliance required by August 3, 2026.

Werewolf Therapeutics firmographics

Firmographics
Name
Werewolf Therapeutics
Legal name
Werewolf Therapeutics, Inc.
Website
https://werewolftx.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Werewolf Therapeutics is a clinical-stage oncology biopharmaceutical company developing conditionally activated INDUKINE™ cytokine and INDUCER™ T cell engager therapeutics via its proprietary PREDATOR® protein engineering platform, targeting patients with advanced solid tumors.
Ownership category
akta.pro rank

Werewolf Therapeutics industry classification

Industry
Product category
Immuno-Oncology Biotherapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Oncology biotherapeutics
  • Cancer immunotherapy
  • Protein engineering platform
  • Clinical-stage pharmaceuticals
  • Tumor microenvironment targeting

Where Werewolf Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Werewolf Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pre-Revenue / Clinical Stage: Werewolf Therapeutics is a clinical-stage biopharmaceutical company with no collaboration revenue. The company reported $0M revenue in FY2025 with a net loss of $60.822 million. The company is exploring strategic alternatives including potential sale, merger, licensing deals, or financing to extend operational runway.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Werewolf Therapeutics product offering

Product offering

Core offering

Werewolf Therapeutics develops a pipeline of conditionally activated proinflammatory immune modulators (INDUKINE™ molecules such as WTX-124 IL-2 and WTX-330 IL-12) and conditionally activated T cell engagers (INDUCER™ molecules), all engineered using its proprietary PREDATOR® protein-engineering platform. The molecules are designed to remain inactive systemically and activate selectively within the tumor microenvironment, aiming to deliver validated cytokine and T cell-engaging biology while minimizing off-target toxicities for patients with advanced or metastatic solid tumors.

Product overview

Werewolf Therapeutics is developing a pipeline of conditionally activated proinflammatory immune modulators called INDUKINE™ molecules and next-generation INDUCER™ T cell engagers for cancer and inflammatory disease treatment. The core PREDATOR® protein engineering technology platform enables systemically delivered therapies that remain inactive in peripheral tissue and activate selectively in the tumor microenvironment. Lead candidates include WTX-124 (IL-2, Phase 1/1b) and WTX-330 (IL-12, Phase 1b/2), with earlier-stage pipeline candidates WTX-712 (IL-21), WTX-518 (IL-18), WTX-921 (IL-10), WTX-1011 (STEAP1 T cell engager), and WTX-2022 (CDH6 T cell engager). A partnered program, JZP898 (IFNα, Phase 1), has been acquired by Jazz Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

  • WTX-124

Quantifiable outcome

  • 21-30% objective response rate in heavily pretreated melanoma patients treated with WTX-124
  • +2 more outcomes

Companies that use Werewolf Therapeutics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Werewolf Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Werewolf Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Jazz PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerJazz Pharmaceuticals acquired JZP898 (formerly WTX-613), a systemically delivered conditionally activated Interferon alpha (IFNα) INDUKINE molecule being developed for refractory and/or immunologically unresponsive tumors. Werewolf out-licensed this partnered program to Jazz.
  • HonorHealth Research InstituteminorStrategic or Co-development PartnerClinical trial partner conducting Phase 1/1b trial of WTX-124. A patient at HonorHealth achieved complete response and has been in remission for over a year - featured in company's Full Moon Moment campaign.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Werewolf Therapeutics competitors and assessment

Company assessment

Direct peers

  • Adagene: Clinical-stage immuno-oncology company developing conditionally activated antibodies using its SAFEbody® masking platform; comparable in approach to targeting tumor microenvironment while sparing healthy tissue.
  • Compugen: Clinical-stage immuno-oncology company leveraging computational platform to develop novel cytokine and immune checkpoint targets; comparable in developing innovative cytokine-based cancer immunotherapies.
  • CytomX Therapeutics: Clinical-stage oncology company pioneering Probody® conditionally activated therapeutics with masking technology designed to reduce systemic toxicity—directly comparable to Werewolf's PREDATOR platform and INDUKINE/INDUCER masking approaches.
  • BioAtla: Clinical-stage company developing Conditionally Active Biologics (CABs) that are activated in tumor microenvironment; comparable conditionally activated protein therapeutic platform targeting solid tumors.
  • Harpoon Therapeutics: Developed T cell engagers (HPN328, HPN217) for solid tumors using TriTAC platform; comparable T cell engager approach that ultimately validated exit via Merck acquisition, illustrating strategic outcome pathway for Werewolf.
  • Janux Therapeutics: Clinical-stage developer of tumor-activated T cell engagers (TRACTrs); directly comparable INDUCER-style T cell engager mechanism with tumor-selective activation.
  • Cullinan Oncology: Clinical-stage oncology company developing a diversified pipeline of immuno-oncology candidates including cytokine-based therapies; comparable small-cap clinical-stage model exploring strategic partnerships for individual programs.
  • NextCure: Clinical-stage immuno-oncology company developing novel immunomedicines for solid tumors; comparable small-cap clinical-stage model with similar workforce and pipeline scale.
  • Dragonfly Therapeutics: Developer of cytokine-based immunotherapies including IL-12, IL-15, and IL-21 candidates with TriNKETs platform; directly comparable cytokine-immunotherapy focus overlapping with Werewolf's INDUKINE pipeline.

Emerging players

  • Maverick Therapeutics: Pre-clinical/early-clinical developer of conditionally activated T cell engagers (COBRA platform) acquired by Takeda; comparable T cell engager approach with tumor-selective activation in solid tumors, illustrating strategic acquisition path.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Werewolf Therapeutics social profiles

Digital presence

Werewolf Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Werewolf Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Werewolf Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Werewolf Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Werewolf Therapeutics

What does Werewolf Therapeutics do?

Werewolf Therapeutics develops a pipeline of conditionally activated proinflammatory immune modulators (INDUKINE™ molecules such as WTX-124 IL-2 and WTX-330 IL-12) and conditionally activated T cell engagers (INDUCER™ molecules), all engineered using its proprietary PREDATOR® protein-engineering platform. The molecules are designed to remain inactive systemically and activate selectively within the tumor microenvironment, aiming to deliver validated cytokine and T cell-engaging biology while minimizing off-target toxicities for patients with advanced or metastatic solid tumors.

Is Werewolf Therapeutics a public or private company?

Werewolf Therapeutics is a public company. It is classified as public and is currently operating.

When was Werewolf Therapeutics founded?

Werewolf Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Werewolf Therapeutics based?

Werewolf Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Werewolf Therapeutics make money?

One revenue line is on record: pre-Revenue / Clinical Stage.

Who are Werewolf Therapeutics's main competitors?

Direct peers on record are Adagene, Compugen, CytomX Therapeutics, BioAtla, Harpoon Therapeutics, Janux Therapeutics, Cullinan Oncology, NextCure and Dragonfly Therapeutics. Maverick Therapeutics is listed as an emerging player.

Does Werewolf Therapeutics have an API?

No public API is recorded for Werewolf Therapeutics.

What industry is Werewolf Therapeutics in?

Werewolf Therapeutics's product category is Immuno-Oncology Biotherapeutics. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanWerewolf Therapeutics, FDA Align on WTX-124 18 mg DoseWerewolf Therapeutics presented Phase 1/1b data for WTX-124 and Phase 1b/2 data for WTX-330 at SITC 2026, showing clinical activity in treatment-refractory solid tumors. The company aligned with the FDA on an 18 mg IV Q2W recommended Phase 2 dose for WTX-124, and WTX-330 showed a confirmed partial response in gallbladder cancer.Business & FinancialWerewolf Therapeutics Selected For Oral Presentation And To Present Posters At The Society For Immunotherapy Of Cancer's (SITC) 2026 Annual MeetingWerewolf Therapeutics will present an oral abstract and a poster at the Society for Immunotherapy of Cancer's 2026 annual meeting. The oral presentation covers a Phase 1/1b study of WTX-124 with pembrolizumab, and the poster covers a Phase 1b/2 study of WTX-330 in relapsed/refractory solid tumors.Stock TitanWerewolf Therapeutics Selected for SITC Oral TalkWerewolf Therapeutics will present an oral talk and two posters at the Society for Immunotherapy of Cancer's 2026 Annual Meeting in Phoenix, November 4-8. The oral presentation covers a Phase 1/1b study of WTX-124, and one poster covers WTX-330.Ticker ReportWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $4.00 According to AnalystsAnalysts rate Werewolf Therapeutics with an average "Hold" and a $4.00 price target. The company beat Q2 EPS estimates at $0.08 versus -$0.28, with revenue of $21.00 million. Insider Luke Evnin sold 107,429 shares at $0.31.American Banking and Market NewsAnalyzing Yarrow Bioscience (NASDAQ:YARW) & Werewolf Therapeutics (NASDAQ:HOWL)Yarrow Bioscience and Werewolf Therapeutics are compared on institutional ownership, profitability, and analyst ratings. Werewolf Therapeutics beats Yarrow on 7 of 13 factors, with a consensus target price of $4.00 versus $58.00 for Yarrow, implying a 330% upside.Markets DailyYarrow Bioscience (NASDAQ:YARW) & Werewolf Therapeutics (NASDAQ:HOWL) Financial ComparisonWerewolf Therapeutics and Yarrow Bioscience are compared on profitability, ownership, volatility, and analyst ratings. Werewolf has higher revenue ($21M vs $570K) and lower beta (0.51 vs 2.01), while Yarrow trades at a lower P/E. Analysts favor Werewolf with a 306.5% upside target versus Yarrow's 121.88%.FinancialContent Business PageBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (NasdaBrodsky & Smith notified investors of investigations into four merger deals: Werewolf Therapeutics, Beazer Homes USA, Lantheus Holdings, and MarketAxess Holdings. The investigations question whether the boards breached fiduciary duties by failing to conduct a fair process and pay fair value. No specific outcomes or timelines were disclosed.GurufocusAre MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?Halper Sadeh LLC is investigating MarketAxess, Werewolf Therapeutics, and Personalis for potential securities law violations and fiduciary breaches. The firm seeks increased consideration or additional disclosures for shareholders in these proposed transactions.FinancialContent Business PageBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BBrodsky & Smith notified investors of investigations into four merger deals: Personalis, Werewolf Therapeutics, Beazer Homes USA, and MarketAxess Holdings. The investigations question whether the boards breached fiduciary duties by failing to conduct a fair process and pay fair value. No cost or financial obligation is imposed on shareholders.PR NewswireAre MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?Halper Sadeh LLC is investigating MarketAxess, Werewolf Therapeutics, and Personalis for potential securities law violations and fiduciary breaches. The firm seeks increased consideration, additional disclosures, or other relief for shareholders in these proposed transactions.